Status:
COMPLETED
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Hepatitis C Infection
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatiti...
Eligibility Criteria
Inclusion
- Key
- Patients chronically infected with hepatitis C virus (HCV) genotype 1
- HCV RNA viral load of ≥10\*5\* IU/mL (100,000 IU/mL) at screening
- Treatment naive
- Key
Exclusion
- Women of child-bearing potential
- Cirrhosis
- Coinfection with HIV or hepatitis B virus
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00874770
Start Date
June 1 2009
End Date
January 1 2011
Last Update
October 23 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Liver & Digestive Specialists (Alds)
Montgomery, Alabama, United States, 36116
2
University Of Colorado Denver & Hospital
Aurora, Colorado, United States, 80045
3
Yale University School Of Medicine
New Haven, Connecticut, United States, 06520
4
Mercy Medical Center
Baltimore, Maryland, United States, 21202